Meeting
2012 Breast Cancer Symposium
Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.
Authors
Susan Dent
Ottawa Hospital Cancer Centre
Susan Dent , Freya Crawley , Nadine Graham , Michelle Campbell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Poster Discussion Session B
Track
Survivorship and Health Policy,Systemic Therapy
Sub Track
Survivorship
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 68)
DOI
10.1200/jco.2012.30.27_suppl.68
Abstract #
68
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).
First Author: Fionnuala Crowley
Poster
2013 ASCO Annual Meeting
Racial disparities in initiation of endocrine therapy for early-stage breast cancer.
First Author: Katherine Elizabeth Reeder-Hayes
Poster
2022 ASCO Annual Meeting
Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data.
First Author: Dawood Findakly
Poster
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
First Author: Ryan Tooker